Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Food supply chains were disturbed by the pandemic, but Zoetis is confident looking into the future.

How This Animal Health Company Was Disrupted by the Coronavirus

BlackBerry

LM Ericsson Telefon

Hannon Armstrong Sustainable Infrastructure Capital

Hercules Capital

Some of the best tech stocks to buy are lesser known companies leading key innovations. Here are six oddballs many investors are overlooking.

6 Forgotten Tech Stocks to Buy Now

Chewy

Freshpet

These are three of best pet stocks to buy now. Each is riding the recent wave of pet ownership due to the novel coronavirus.

3 of the Best Pet Stocks to Buy Now

Blackrock Inc

Salesforce

Deere & Company

Microsoft

Progressive

Environmental, Social and Governance investing may seem counter to maximizing profits, but the best ESG stocks deliver for all stakeholders.

7 ESG Stocks That Will Deliver for Every Stakeholder

ORLANDO, Fla., Aug. 17, 2020 /PRNewswire/ -- The North American Veterinary Community (NAVC) today announced the opening of the Zoetis VMX Virtual Expo Hall booth, providing year-round opportunities for veterinary professionals to engage with and learn about the company's new products,.

NAVC Announces Zoetis Joins VMX Virtual Expo Hall Opening The Doors For New Interactive And Innovative Ways To Engage And Educate Veterinary Professionals Year-Round

Zoetis' (ZTS) CEO Kristin Peck on Q2 2020 Results - Earnings Call Transcript

Its companion-animal products continue to be the sweet spot for the animal health company.

How Zoetis Beat Expectations Again in Q2

Zoetis (ZTS) delivered earnings and revenue surprises of 34.85% and 13.88%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) Q2 Earnings and Revenues Beat Estimates

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis reports second quarter 2020 financial results.

Zoetis Announces Second Quarter 2020 Results

Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?

Amgen

BioMarin Pharmaceutical

Eli Lilly

Regeneron Pharmaceuticals

Seagen

Vertex Pharmaceuticals

The health care sector has been a big winner in 2020, far outpacing the Dow Jones industrial average and S&P 500.

Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zoetis (ZTS) Hits 52-Week High, Can the Run Continue?

Garmin

Intuit

Are you retiring? Or do you want to build a portfolio that offers steady returns with minimal risk?

Consider Adding Zoetis, Garmin, And Intuit To Your Retirement Portfolio

AbbVie

Horizon Pharma

Novo Nordisk

Dr. Reddy's Labs

United Therapeutics

There’s a select group of pharmaceutical stocks that stand to win without even looking for a Covid-19 cure.
The post The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase appeared first on InvestorPlace.

The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase

SOUTH SAN FRANCISCO, Calif. and PARSIPPANY, N.J., July 7, 2020 /PRNewswire/ -- Trianni, Inc. (TRIANNI) and Zoetis (NYSE: ZTS) today announced a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments. "We are confident...

Trianni and Zoetis Announce Agreement to Develop a Transgenic Antibody Discovery Platform for Use in Animal Health

For investors playing the long game, yes.

Is It Safe to Buy Stocks Now?

Covetrus Inc

Elanco Animal Health Inc

With these three animal-health stocks, your portfolio will be stronger than ever.

3 Top Animal-Health Companies to Buy in June

General Mills

IDEXX Laboratories

Trupanion

The ProShares Pet Care ETF is the only ETF dedicated to pet stocks

These 7 Pet Care Stocks Will Reduce the Cost of Pet Ownership

Zoetis Now A Better Buy Than Gilead

Grifols, S.A.

Johnson & Johnson

Merck

Repligen

Takeda Pharmaceutical

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?

Zoetis (ZTS) Up 13.1% Since Last Earnings Report: Can It Continue?

Bristol-Myers

Sanofi

Pharmaceutical stocks dipped by a single-digit percentage in the first five months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Why These 5 Pharma Stocks Are Outplaying 90% Of The Stock Market

Pacira Pharmaceuticals

PCRX vs. ZTS: Which Stock Is the Better Value Option?

PCRX vs. ZTS: Which Stock Should Value Investors Buy Now?

Amazon

Easterly Government Properties

Nestle SA

Procter & Gamble

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

These long-term stocks make great investments. You can buy them now, examine their fundamentals every month and profit for years to come.

News for Zoetis Stock (ZTS)